Menu Search
Equities

Xbrane Biopharma AB

7XB:BER

Xbrane Biopharma AB

Actions
  • Price (EUR)0.0207
  • Today's Change0.000 / 0.98%
  • Shares traded--
  • 1 Year change-89.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 18:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

  • Revenue in SEK (TTM)199.81m
  • Net income in SEK-304.77m
  • Incorporated2008
  • Employees65.00
  • Location
    Xbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
  • Phone+46 855905600
  • Websitehttps://xbrane.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.